☰

Minhee Kang, Ph.D. - Publications

Affiliations: 
2003 Harvard University, Cambridge, MA, United States 
Area:
Biostatistics Biology
Tree Info Similar researchers PubMed Report error

32 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Sherman KE, Rouster SD, Kang M, Umbleja T, Sterling R, Butt AA. PNPLA3 Gene Polymorphisms in HCV/HIV-Coinfected Individuals. Digestive Diseases and Sciences. PMID 30218427 DOI: 10.1007/S10620-018-5278-Y  0.34
2018 Cespedes MS, Kang M, Kojic EM, Umbleja T, Godfrey C, Webster-Cyriaque JY, Masih R, Firnhaber C, Grinsztejn B, Saah A, Cu-Uvin S, Aberg JA. Anogenital Human Papillomavirus Virus DNA and Sustained Response to the Quadrivalent HPV Vaccine in Women Living with HIV-1. Papillomavirus Research (Amsterdam, Netherlands). PMID 30118852 DOI: 10.1016/J.Pvr.2018.08.002  0.381
2018 Wyles DL, Kang M, Matining RM, Murphy RL, Peters MG. Similar Low Rates of HCV Recurrence in HCV/HIV- and HCV-Infected Participants who Achieved SVR After DAA Treatment: Interim Results From the ACTG A5320 Viral Hepatitis C Infection Long-term Cohort Study (V-HICS). Open Forum Infectious Diseases. 5: ofy103. PMID 29977962 DOI: 10.1093/Ofid/Ofy103  0.391
2018 Hosseinipour MC, Kang M, Krown SE, Bukuru A, Umbleja T, Martin J, Orem J, Godfrey C, Hoagland B, Mwelase N, Langat D, Nyirenda M, MacRae J, Borok-Williams M, Samaneka W, et al. As-Needed versus Immediate Etoposide Chemotherapy in Combination with Antiretroviral Therapy for Mild or Moderate AIDS-associated Kaposi Sarcoma in Resource-Limited Settings: A5264/AMC-067 Randomized Clinical Trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 29365083 DOI: 10.1093/Cid/Ciy044  0.326
2017 Shive CL, Judge CJ, Clagett B, Kalayjian RC, Osborn M, Sherman KE, Fichtenbaum C, Gandhi RT, Kang M, Popkin DL, Sieg SF, Lederman MM, Rodriguez B, Anthony DD. Pre-vaccine plasma levels of soluble inflammatory indices negatively predict responses to HAV, HBV, and tetanus vaccines in HCV and HIV infection. Vaccine. PMID 29254840 DOI: 10.1016/J.Vaccine.2017.12.018  0.421
2017 Tam E, Luetkemeyer AF, Mantry PS, Satapathy SK, Ghali P, Kang M, Haubrich R, Shen X, Ni L, Camus G, Copans A, Rossaro L, Guyer B, Brown RS. Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naive patients: findings from two randomized trials. Liver International : Official Journal of the International Association For the Study of the Liver. PMID 29091342 DOI: 10.1111/Liv.13616  0.328
2017 Sherman KE, Kang M, Sterling R, Umbleja T, Marks K, Kiser JJ, Alston-Smith B, Greaves W, Butt AA, The Actg Birth Study Team. Phase 3 trial of first generation protease inhibitor therapy for hepatitis C virus/human immunodeficiency virus coinfection. World Journal of Hepatology. 9: 217-223. PMID 28217259 DOI: 10.4254/Wjh.V9.I4.217  0.323
2016 Judge CJ, Sandberg JK, Funderburg NT, Sherman KE, Butt AA, Kang M, Landay AL, Lederman MM, Anthony DD. CD14brightCD16- monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy. Journal of Acquired Immune Deficiency Syndromes (1999). PMID 27258231 DOI: 10.1097/Qai.0000000000001104  0.333
2016 Petersen T, Lee YJ, Osinusi A, Amorosa VK, Wang C, Kang M, Matining R, Zhang X, Dou D, Umbleja T, Kottilil S, Peters MG. Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin. Aids Research and Human Retroviruses. PMID 26974581 DOI: 10.1089/Aid.2015.0236  0.356
2016 Jacobson J, Bosinger S, Kang M, Belaunzaran-Zamudio P, Matining RM, Wilson C, Flexner CW, Clagett B, Plants J, Read S, Purdue L, Myers L, Boone L, Tebas P, Kumar P, et al. The Effect of Chloroquine on Immune Activation and Interferon Signatures Associated with HIV-1. Aids Research and Human Retroviruses. PMID 26935044 DOI: 10.1089/Aid.2015.0336  0.347
2015 Bedimo R, Kang M, Tebas P, Overton ET, Hollabaugh K, McComsey GA, Bhattacharya D, Evans C, Brown T, Taiwo B. Effects of Pegylated Interferon/Ribavirin on Bone Turnover Markers (BTMs) in HIV/HCV Co-Infected Patients. Aids Research and Human Retroviruses. PMID 26499270 DOI: 10.1089/Aid.2015.0204  0.353
2015 Sherman K, Kang M, Sterling R, Umbleja T, Marks KM, Alston-Smith B, Greaves W. A Prospective Phase 3 Trial of Boceprevir/Pegylated Interferon/Ribavirin for HCV/HIV Coinfected Persons Open Forum Infectious Diseases. 2. DOI: 10.1093/Ofid/Ofv133.619  0.364
2014 Kojic EM, Kang M, Cespedes MS, Umbleja T, Godfrey C, Allen RT, Firnhaber C, Grinsztejn B, Palefsky JM, Webster-Cyriaque JY, Saah A, Aberg JA, Cu-Uvin S. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 59: 127-35. PMID 24723284 DOI: 10.1093/Cid/Ciu238  0.435
2014 Sulkowski MS, Kang M, Matining R, Wyles D, Johnson VA, Morse GD, Amorosa V, Bhattacharya D, Coughlin K, Wong-Staal F, Glesby MJ. Safety and antiviral activity of the HCV entry inhibitor ITX5061 in treatment-naive HCV-infected adults: a randomized, double-blind, phase 1b study. The Journal of Infectious Diseases. 209: 658-67. PMID 24041792 DOI: 10.1093/Infdis/Jit503  0.336
2013 Amorosa VK, Luetkemeyer A, Kang M, Johnson VA, Umbleja T, Haas DW, Yesmin S, Bardin MC, Chung RT, Alston-Smith B, Tebas P, Peters MG. Addition of nitazoxanide to PEG-IFN and ribavirin to improve HCV treatment response in HIV-1 and HCV genotype 1 coinfected persons naïve to HCV therapy: results of the ACTG A5269 trial. Hiv Clinical Trials. 14: 274-83. PMID 24334180 DOI: 10.1310/Hct1406-274  0.344
2013 Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ. In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use. The American Journal of Clinical Nutrition. 98: 423-9. PMID 23739141 DOI: 10.3945/Ajcn.112.048785  0.373
2012 Kang M, Cu-Uvin S. Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy. Hiv Medicine. 13: 372-8. PMID 22257000 DOI: 10.1111/J.1468-1293.2011.00979.X  0.395
2011 Anthony DD, Umbleja T, Aberg JA, Kang M, Medvik K, Lederman MM, Peters MG, Koziel MJ, Overton ET. Lower peripheral blood CD14+ monocyte frequency and higher CD34+ progenitor cell frequency are associated with HBV vaccine induced response in HIV infected individuals Vaccine. 29: 3558-3563. PMID 21397720 DOI: 10.1016/J.Vaccine.2011.02.092  0.342
2010 Overton ET, Kang M, Peters MG, Umbleja T, Alston-Smith BL, Bastow B, Demarco-Shaw D, Koziel MJ, Mong-Kryspin L, Sprenger HL, Yu JY, Aberg JA. Immune response to hepatitis B vaccine in HIV-infected subjects using granulocyte-macrophage colony-stimulating factor (GM-CSF) as a vaccine adjuvant: ACTG study 5220. Vaccine. 28: 5597-604. PMID 20600512 DOI: 10.1016/J.Vaccine.2010.06.030  0.399
2007 Kang M, Chung RT. The role of early viral decline in the treatment of hepatitis C in HIV-1-coinfected persons. Journal of Acquired Immune Deficiency Syndromes (1999). 46: 371-3. PMID 18090301 DOI: 10.1097/Qai.0B013E3180Dec9Fc  0.344
2007 Aweeka FT, Kang M, Yu JY, Lizak P, Alston B, Chung RT. Pharmacokinetic evaluation of the effects of ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team. Hiv Medicine. 8: 288-94. PMID 17561874 DOI: 10.1111/j.1468-1293.2007.00472.x  0.324
2007 Blackard JT, Kang M, St Clair JB, Lin W, Kamegaya Y, Sherman KE, Koziel MJ, Peters MG, Andersen J, Chung RT. Viral factors associated with cytokine expression during HCV/HIV co-infection. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 27: 263-9. PMID 17477814 DOI: 10.1089/Jir.2006.0147  0.407
2007 Kang M, Lagakos SW. Statistical methods for panel data from a semi-Markov process, with application to HPV. Biostatistics (Oxford, England). 8: 252-64. PMID 16740624 DOI: 10.1093/Biostatistics/Kxl006  0.52
2006 Blackard JT, Kang M, Sherman KE, Koziel MJ, Peters MG, Chung RT. Effects of HCV treatment on cytokine expression during HCV/HIV coinfection. Journal of Interferon & Cytokine Research : the Official Journal of the International Society For Interferon and Cytokine Research. 26: 834-8. PMID 17115902 DOI: 10.1089/Jir.2006.26.834  0.354
2006 Liddicoat RV, Losina E, Kang M, Freedberg KA, Walensky RP. Refusing HIV testing in an urgent care setting: results from the "Think HIV" program. Aids Patient Care and Stds. 20: 84-92. PMID 16475889 DOI: 10.1089/Apc.2006.20.84  0.3
2004 Kang M, Lagakos SW. Evaluation of log-rank tests for infrequent observations from a multi-state process, with application to HPV vaccine efficacy. Statistics in Medicine. 23: 3681-96. PMID 15534891 DOI: 10.1002/Sim.1916  0.582
2004 Kang M, Lagakos SW. Evaluating the role of human papillomavirus vaccine in cervical cancer prevention. Statistical Methods in Medical Research. 13: 139-55. PMID 15068258 DOI: 10.1191/0962280204Sm358Ra  0.569
2001 McFarland EJ, Borkowsky W, Fenton T, Wara D, McNamara J, Samson P, Kang M, Mofenson L, Cunningham C, Duliege AM, Sinangil F, Spector SA, Jimenez E, Bryson Y, Burchett S, et al. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. The Journal of Infectious Diseases. 184: 1331-5. PMID 11679925 DOI: 10.1086/323994  0.339
2001 Cunningham CK, Wara DW, Kang M, Fenton T, Hawkins E, McNamara J, Mofenson L, Duliege AM, Francis D, McFarland EJ, Borkowsky W. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-1-infected women. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 32: 801-7. PMID 11229849 DOI: 10.1086/319215  0.301
2000 Borkowsky W, Wara D, Fenton T, McNamara J, Kang M, Mofenson L, McFarland E, Cunningham C, Duliege AM, Francis D, Bryson Y, Burchett S, Spector SA, Frenkel LM, Starr S, et al. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gp120 vaccines. AIDS Clinical Trial Group 230 Collaborators. The Journal of Infectious Diseases. 181: 890-6. PMID 10720509 DOI: 10.1086/315298  0.38
2000 Stiehm ER, Fletcher CV, Mofenson LM, Palumbo PE, Kang M, Fenton T, Sapan CV, Meyer WA, Shearer WT, Hawkins E, Fowler MG, Bouquin P, Purdue L, Sloand EM, Nemo GJ, et al. Use of human immunodeficiency virus (HIV) human hyperimmune immunoglobulin in HIV type 1-infected children (Pediatric AIDS clinical trials group protocol 273). The Journal of Infectious Diseases. 181: 548-54. PMID 10669338 DOI: 10.1086/315224  0.347
1998 Lambert JS, McNamara J, Katz SL, Fenton T, Kang M, VanCott TC, Livingston R, Hawkins E, Moye J, Borkowsky W, Johnson D, Yogev R, Duliege AM, Francis D, Gershon A, et al. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV- infected infants and children Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. 19: 451-461. PMID 9859958 DOI: 10.1097/00042560-199812150-00003  0.383
Show low-probability matches.